Contact Us   |   Sign In   |   Join CAHR
Market Access 201 - June 19, 2018
Share |


Flying Blind – Navigating Patient Access through Uncertainty

Tuesday, June 19, 2018
  The Westin Toronto Airport
  950 Dixon Road Toronto, ON M9W 5N4

Join us for Market Access 201 as we explore the evolving reimbursement landscape in Canada, and discuss how patient access may be impacted by an increasingly uncertain reimbursement environment.

WHO SHOULD ATTEND? Anyone who wants to learn more about market access should consider joining us, and if you are seeking your Market Access Certification through our CMAP program this is a must-attend event!



8:30 AM -8:35 AM | Opening Remarks

8:35 AM - 8:45 AM | EMCEE FOR THE DAY: Jeffrey Hoch, PhD, Professor, Department of Public Health Sciences, Associate Director, Center for Healthcare Policy and Research UC Davis

8:45 AM - 10:00 AM | PANEL ONE

Patented Medicine Prices Review Board (PMPRB)
This panel will explore questions about how the PMPRB consultations will unfold, how the remaining details will be developed, what transition measures will look like and what impact the final guidelines will have on current prices and new drug prices.

MODERATOR: Joan McCormick, Principal, IQVIA

  Matt Kellison,
PMPRB, Director, Regulatory Affairs and Outreach
  Lauren Fischer,
Vice President of Corporate Affairs, Eli Lilly Canada
  Richard Cheung, Partner, Fasken

10:00 AM - 11:00 AM | PANEL TWO

Pharmacoeconomics (PE)
This panel will focus on the growing influence of pharmacoeconomics in the Canadian reimbursement process. It will discuss the implications of the revised CADTH PE guidelines on CDR and pCODR reviews. The panelists will also discuss the implications of using PE thresholds for price regulations. In addition, the impact of PE models on pCPA negotiations will also be explored in this session.

MODERATOR: Chris Cameron, Senior Director, Cornerstone Research Group

 Professor Doug Coyle
, (Interim Director and Professor) School of Epidemiology and Public Health
 Don Husereau,
Senior Associate, Institute for Health Economics
 Brad Alyward,
Principal Consultant, MORSE Consulting Inc.
 Joan McCormick,
Principal, IQVIA


11:00 AM - 11:15 AM | Networking Break

11:15 AM - 12:00 PM | PANEL THREE

Health Technology Assessment (HTA)

Canada’s centralized HTA agency CADTH has recently released a new 3-year strategic plan that marks a shift from its previous vision. Noteworthy is the focus of recommendations on alignment of drug assessment with the priorities of the participating plans over all phases of the technology life cycle. Join us to hear CADTH describe their new strategic plan, how their mandate has evolved, why change is needed, and the implications for industry.

MODERATOR: Angela Rocchi,
Principal, Athena Research

  Dr. Tammy Clifford,
CADTH’s Chief Scientist and Vice President, Evidence Standards

12:00 PM - 1:00 PM | Lunch

1:00 PM - 2:00 PM | PANEL FOUR

Pan-Canadian Pharmaceutical Alliance (pCPA)
This panel will focus on recent events surrounding the pCPA and how public payers believe that PMPRB reform may impact upcoming pCPA negotiations.

MODERATOR: Sherry O’Quinn, Managing Principal, MORSE

   Imran Ali,
Senior Manager, pan-Canadian Pharmaceutical Alliance (pCPAO)
  Jessica Arias,
Program Manager, Cancer Care Ontario
  Heather McDonald,
Vice President and Head Market Access & Government Affairs, Bayer

2:00 - 2:45 PM | PANEL FIVE

Patient Support Programs (PSPs)
This session will help participants develop a better understanding of why PSPs are well-suited to support the development of outcomes-based agreements. It will suggest effective ways that PSPs can be developed to support data collection for HTA. Finally, current pCPA perspectives on PSPs and the opportunity for data collection within programs will be explored by this panel.

MODERATOR: Allison Wills,
Partner, 20Sense Specialty Pharmaceutical Consulting

   Sang Mi Lee,
Senior Pharmacist, pCPA Office
   Greg Rutherford, Director Pharmaceutical Solutions, McKesson
   Janey Shin, Director, RWE, Janssen


2:45PM - 3:15PM | Networking Break

3:15 PM - 4:30 PM | PANEL SIX

Presidents’ Roundtable
This session will bring together general managers from three innovative pharmaceutical companies operating in Canada to explore their insights on how the current reimbursement environment is impacting their company, its decision-making and patient access.

Barbara Jaszewski, former VP Global Pricing and Market Access, Lundbeck

   Peter Brenders,
General Manager, Sanofi Genzyme Canada
   Brian Canestraro,
General Manager Intercept Pharmaceuticals
   Ben Faienza,
Country Representative, UCB Canada

CAHR reserves the right to cancel or change speakers, program content and date without prior notice.
We assume no liability for these changes

For more information please contact the CAHR office. 416.494.1440 x221 or email at

4:30 - 4:35 PM | Closing Remarks


 Thank you to our partners!



Membership Software Powered by YourMembership  ::  Legal